Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial.

Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q, Sun L, Luo B, Shang L, Chen W, Bai Y, Tang M, He M, Wu L, Ma Q, Hou D, He J. Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial. Age Ageing. 2017 09 01; 46(5):767-773.

View in: PubMed

subject areas

Acetylcholinesterase
Activities of Daily Living
Aged
Aged, 80 and over
Alzheimer Disease
Aminacrine
China
Cholinesterase Inhibitors
Cognition
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Neuropsychological Tests
Severity of Illness Index
Time Factors
Treatment Outcome

authors with profiles

Lang Wu, PhD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support